JTO：中国科学家+中国创新药，首次证实免疫单药新辅助治疗能为早期肺癌病变带来长期生存获益

接纳不同放射治疗方式也病症的三年肾功能变化

总而言之，本次研究课题进一步指引了PD-1衍生物作为NSCLC原先专用放射治疗的合理性和可行性，特别是现阶段证实了致病单药放射治疗的依然共存获益，且致病原先专用放射治疗也许对PD-L1阴性、癌细胞突变负重较低的病症具备较好的临床镇痛。该研究课题为适用致病疗法作为NSCLC的原先专用放射治疗提供了原先的观念。

参考文献：

[1]SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer Statistics, 2021 [J]. CA Cancer J Clin, 2021, 71(1): 7-33.

[2]XIA C, DONG X, LI H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants [J]. Chin Med J (Engl), 2022, 135(5): 584-590.

[3]BURDETT S, PIGNON J P, TIERNEY J, et al. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer [J]. Cochrane Database Syst Rev, 2015, (3): CD011430.

[4]JIA X H, XU H, GENG L Y, et al. Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis [J]. Lung Cancer, 2020, 147: 143-153.

[6]ZHANG F, GUO W, ZHOU B, et al. Research article: Three-year Follow-up of Neoadjuvant PD-1 inhibitor (Sintilimab) in Non-Small Cell Lung Cancer [J]. J Thorac Oncol, 2022.